A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
Why it’s critical to close open steps in cell therapy manufacturing
Why it’s critical to close open steps in cell therapy manufacturing
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
UniQure falls further on Makary comments
UniQure falls further on Makary comments
Moderna’s combination flu, COVID shot wins over European drug regulators
Moderna’s combination flu, COVID shot wins over European drug regulators
Generate caps a strong month for biotech IPOs with $400M offering
Generate caps a strong month for biotech IPOs with $400M offering
Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
Boehringer drug approved in 44 days; BioMarin shelves Roctavian
Boehringer drug approved in 44 days; BioMarin shelves Roctavian
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
Alkermes’ Richard Pops to step down after three-decade run as CEO
Alkermes’ Richard Pops to step down after three-decade run as CEO
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
15 states sue HHS over changes to childhood vaccine schedule
15 states sue HHS over changes to childhood vaccine schedule
With Vivtex deal, Novo gains a chance at better oral obesity drugs
With Vivtex deal, Novo gains a chance at better oral obesity drugs
BreezeBio banks $60M to make more precise genetic medicines
BreezeBio banks $60M to make more precise genetic medicines
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
Novo to cut GLP-1 drug prices; Palvella soars on study data
Novo to cut GLP-1 drug prices; Palvella soars on study data
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page